138 related articles for article (PubMed ID: 20713906)
41. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients.
Nadar S; Blann AD; Lip GY
Am J Hypertens; 2006 Sep; 19(9):970-7; discussion 978. PubMed ID: 16942942
[TBL] [Abstract][Full Text] [Related]
42. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
[TBL] [Abstract][Full Text] [Related]
43. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery.
Zimmermann N; Wenk A; Kim U; Kienzle P; Weber AA; Gams E; Schrör K; Hohlfeld T
Circulation; 2003 Aug; 108(5):542-7. PubMed ID: 12874188
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry.
Pedersen SB; Grove EL; Nielsen HL; Mortensen J; Kristensen SD; Hvas AM
Platelets; 2009 Sep; 20(6):415-20. PubMed ID: 19658002
[TBL] [Abstract][Full Text] [Related]
45. Alternative splicing of platelet cyclooxygenase-2 mRNA in patients after coronary artery bypass grafting.
Censarek P; Steger G; Paolini C; Hohlfeld T; Grosser T; Zimmermann N; Fleckenstein D; Schrör K; Weber AA
Thromb Haemost; 2007 Dec; 98(6):1309-15. PubMed ID: 18064329
[TBL] [Abstract][Full Text] [Related]
46. Platelet activity and outcome after intracerebral hemorrhage.
Naidech AM; Bernstein RA; Levasseur K; Bassin SL; Bendok BR; Batjer HH; Bleck TP; Alberts MJ
Ann Neurol; 2009 Mar; 65(3):352-6. PubMed ID: 19334079
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry.
Lordkipanidzé M; Pharand C; Schampaert E; Palisaitis DA; Diodati JG
Thromb Res; 2009 Sep; 124(4):418-22. PubMed ID: 19250657
[TBL] [Abstract][Full Text] [Related]
48. Aspirin response variability assessed with the PFA-100 device.
Reny JL; Quéré I; de Moerloose P; Fontana P
Thromb Haemost; 2008 May; 99(5):968-9; author reply 969. PubMed ID: 18449432
[No Abstract] [Full Text] [Related]
49. Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke.
Karepov V; Tolpina G; Kuliczkowski W; Serebruany V
Cerebrovasc Dis; 2008; 26(3):272-6. PubMed ID: 18648200
[TBL] [Abstract][Full Text] [Related]
50. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment.
Paniccia R; Antonucci E; Gori AM; Marcucci R; Poli S; Romano E; Valente S; Giglioli C; Fedi S; Gensini GF; Abbate R; Prisco D
Am J Clin Pathol; 2007 Jul; 128(1):143-9. PubMed ID: 17580282
[TBL] [Abstract][Full Text] [Related]
51. Heritability, platelet function, and aspirin: a link established but cause unknown.
Freedman JE
Circulation; 2007 May; 115(19):2468-70. PubMed ID: 17502587
[No Abstract] [Full Text] [Related]
52. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
[TBL] [Abstract][Full Text] [Related]
53. Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism.
Kranzhofer R; Ruef J
Platelets; 2006 May; 17(3):163-9. PubMed ID: 16702043
[TBL] [Abstract][Full Text] [Related]
54. Can platelet function tests predict the clinical efficacy of aspirin?
Haubelt H; Anders C; Hellstern P
Semin Thromb Hemost; 2005; 31(4):404-10. PubMed ID: 16149017
[TBL] [Abstract][Full Text] [Related]
55. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
[TBL] [Abstract][Full Text] [Related]
56. Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease.
Narvaez I; Sagastagoitia JD; Vacas M; Saez Y; Lafita M; Monica S; de Lafuente JP; Molinero E; Iriarte JA
Thromb Res; 2007; 120(5):671-7. PubMed ID: 17331566
[TBL] [Abstract][Full Text] [Related]
57. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Schrör K
Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
[TBL] [Abstract][Full Text] [Related]
58. Appropriate assessment of the functional consequences of platelet cyclooxygenase-1 inhibition by aspirin in vivo.
Ofosu FA
Thromb Res; 2014 May; 133(5):697-8. PubMed ID: 24315499
[No Abstract] [Full Text] [Related]
59. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
60. Platelets and antiplatelet therapy in patients with diabetes mellitus.
Arjomand H; Roukoz B; Surabhi SK; Cohen M
J Invasive Cardiol; 2003 May; 15(5):264-9. PubMed ID: 12730635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
